Tempus AI

Tempus AI analyzes genomic sequencing, medical imaging, and clinical records to identify patterns in cancer care and cardiology, helping physicians make more personalized treatment decisions. It went public on Nasdaq in 2024, giving public markets a direct read on how well AI-driven precision medicine businesses can actually scale and turn a profit.